Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epidermal growth factor receptor truncated (EGFRt) refers to a modified form of EGFR where portions of the extracellular or intracellular domain have been removed or altered. While naturally occurring truncations in cancer can drive oncogenic signaling, engineered truncated forms are commonly used as non-signaling surface markers for tracking genetically modified cells, such as CAR-T cells. These engineered versions retain antibody recognition sites but lack functional kinase activity.
Varies depending on the specific truncation. Wild-type EGFR activates downstream signaling cascades including MAPK/ERK and PI3K/AKT pathways. Truncated forms, particularly engineered ones, are often designed to be non-signaling and used as surface markers. Naturally occurring truncations can exhibit constitutive activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epidermal Growth Factor Receptor Truncated (EGFRt).